HRTS250117C30000
- 0.00
- 0.000.00%
Tema GLP-1, Obesity & Cardiometabolic ETF Newsroom
The humanoid robot standing next to Jensen Huang is entering the ChatGPT moment.
This is an important breakthrough for embodied intelligence because it helps Siasun Robot&Automation tackle one of the biggest bottlenecks on the path to generalization: the problem of 'scarcity of high-quality data,' creating realistic environments and perceiving objects for humanoid robots.
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Key Deals This Week: FuboTV - Disney, Constellation Energy, Eli Lilly, Phillips 66, Intercontinental Exchange and More
CMS Proposes 4.33% Increase for Medicare Advantage Plans
Catalyst Watch: Bank Earnings, Oil Updates, Powerhouse Conferences in Retail and Healthcare
Lilly Signs Licensing Deal With Mediar for IPF Drug
"Eli Lilly In Advanced Talks To Buy U.S. Cancer Biotech For Up To $2.5B; Scorpion's Drug Candidate Inhibits A Mutation That Is A Major Driver Of Breast, Gynaecological And Head And Neck Cancers" - Financial Times
Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals
UnitedHealth Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Vertex Pharmaceuticals Analyst Ratings
HIMS Downgraded, Agilon Upgraded at Citi in 2025 Health Tech Review
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Cytokinetics Analyst Ratings
On Thursday, Alchemab Therapeutics Entered A Collaboration With Eli Lilly To Discover, Develop, And Commercialize Up To Five Therapeutics For Amyotrophic Lateral Sclerosis; Alchemab Will Receive An Undisclosed Upfront Payment And Is Eligible To...
Morgan Stanley's outlook for the top ten investment trends in 2025: the revival of nuclear energy, the AI revolution in the financial Industry, quantum computing, oral weight loss medications...
Morgan Stanley pointed out that historically, popular themes with strong profit momentum tend to have a strong sustainability, such as AI, defense spending, and obesity drugs; negative prices and quantum computing are expected to emerge as new investment hotspots.
The sudden drop of Fast Retailing is a burden.
The Nikkei average has fallen for three consecutive days, closing down 414.69 yen at 39,190.40 yen (estimated Volume 1.7 billion 30 million shares), below the psychological threshold of 39,500 yen. The operating profit for Fast Retailing <9983> for the September-November 2024 period announced the previous day fell below market Financial Estimates, causing the company's stock to drop nearly 8% at one point. The decline widened toward the middle of the morning session, reaching as low as 39,166.05 yen. However, due to the consecutive declines, there was buying aimed at a rebound in the afternoon session.
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
Evaluating UnitedHealth Group Against Peers In Health Care Providers & Services Industry